We are live on
!
Find out more
First Manhattan Portfolio holdings
AUM
$36.1B
1-Year Est. Return
11.5%
This Fund
S&P 500
This Quarter
Est. Return
+9.64%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$27.3B
AUM Growth
+$1.22B
(+4.7%)
Cap. Flow
-$932M
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
60.57%
Holding
1,588
New
70
Increased
176
Reduced
495
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$128M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$67.4M |
| 3 |
XIFR
XPLR Infrastructure LP
XIFR
|
+$63.8M |
| 4 |
UnitedHealth
UNH
|
+$57.4M |
| 5 |
Danaher
DHR
|
+$24.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$760M |
| 2 |
Amazon
AMZN
|
+$68.5M |
| 3 |
AbbVie
ABBV
|
+$54.2M |
| 4 |
PPLI
People Inc
PPLI
|
+$36.8M |
| 5 |
PNC Financial Services
PNC
|
+$29.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 44.09% |
| 2 | Technology | 18.28% |
| 3 | Healthcare | 10.34% |
| 4 | Consumer Discretionary | 7.89% |
| 5 | Communication Services | 5.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
TripAdvisor
TRIP
$1.59B
| $65.1K | ﹤0.01% |
3,950
| – | – |
|
827
iShares MSCI EAFE Growth ETF
EFG
$16.3B
| $64.6K | ﹤0.01% |
677
| – | – |
|
828
Medifast
MED
$108M
| $64.5K | ﹤0.01% |
700
| – | – |
|
829
APA Corp
APA
$12.8B
| $64.3K | ﹤0.01% |
1,881
| – | – |
|
830
Sony
SONY
$123B
| $64.2K | ﹤0.01% |
3,565
-10,000
| -74% | -$188K |
|
831
Fidelity National Financial
FNF
$13.9B
| $62.5K | ﹤0.01% |
1,735
-1,171
| -40% | -$40.8K |
|
832
Sonoco
SON
$5.76B
| $62K | ﹤0.01% |
1,050
-11,000
| -91% | -$662K |
|
|
JHG
833
DELISTED
Janus Henderson
JHG
| $61.7K | ﹤0.01% |
2,265
| – | – |
|
834
Ginkgo Bioworks
DNA
$481M
| $61.6K | ﹤0.01% |
828
| – | – |
|
835
State Street Industrial Select Sector SPDR ETF
XLI
$33.9B
| $60K | ﹤0.01% |
559
| – | – |
|
836
iShares MSCI EAFE ETF
EFA
$76.4B
| $59.9K | ﹤0.01% |
826
-1,476
| -64% | -$107K |
|
837
Lam Research
LRCX
$382B
| $59.8K | ﹤0.01% |
930
+300
| +48% | +$16.9K |
|
|
DFS
838
DELISTED
Discover Financial Services
DFS
| $59.6K | ﹤0.01% |
510
-17
| -3% | -$1.78K |
|
839
CDW
CDW
$17.1B
| $58.5K | ﹤0.01% |
319
-625
| -66% | -$109K |
|
840
JPMorgan Equity Premium Income ETF
JEPI
$45.3B
| $58.1K | ﹤0.01% |
1,050
| – | – |
|
841
Telephone and Data Systems
TDS
$3.91B
| $58K | ﹤0.01% |
7,052
-43,827
| -86% | -$372K |
|
842
Titan International
TWI
$516M
| $57.4K | ﹤0.01% |
+5,000
| New | +$53K |
|
843
Insulet
PODD
$11.3B
| $57.4K | ﹤0.01% |
199
| – | – |
|
|
HBI
844
DELISTED
Hanesbrands
HBI
| $57.3K | ﹤0.01% |
12,628
-1,998
| -14% | -$9.13K |
|
845
America Movil
AMX
$78.1B
| $57.2K | ﹤0.01% |
2,644
| – | – |
|
846
MP Materials
MP
$7.35B
| $57.2K | ﹤0.01% |
2,500
| – | – |
|
847
Shopify
SHOP
$148B
| $56.8K | ﹤0.01% |
880
| – | – |
|
|
FITB
848
Fifth Third Bancorp
FITB
$52B
| $56.4K | ﹤0.01% |
2,150
| – | – |
|
849
Journey Medical
DERM
$170M
| $56.1K | ﹤0.01% |
35,294
| – | – |
|
850
Watsco Inc
WSO
$14.9B
| $56.1K | ﹤0.01% |
147
+37
| +34% | +$12.5K |
|
Similar funds
SAM
First Manhattan's Q2 2023 Portfolio in Review
As of Q2 2023, First Manhattan held 1,588 positions worth $27.3B, up 4.7% from $26.1B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
First Manhattan withdrew a net $932M in Q2 2023, closing 161 positions and reducing 495 holdings. Its most notable exit was Enanta Pharmaceuticals, an estimated $10.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 44% of assets, down from 45% a quarter earlier, followed by Technology and Healthcare.
Against the trend, First Manhattan opened a new position in Mersana Therapeutics worth $1.87M.
- First Manhattan's largest Q2 2023 buy was Mersana Therapeutics: 22,784 shares worth $1.87M.
- First Manhattan added most to Thermo Fisher Scientific in Q2 2023, an estimated $128M increase.
- First Manhattan's biggest Q2 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $760M.
- First Manhattan fully exited Enanta Pharmaceuticals in Q2 2023, selling an estimated $10.7M.
- First Manhattan's ten largest holdings make up 61% of its $27.3B portfolio in Q2 2023.
- First Manhattan opened 70 new positions and closed 161 in Q2 2023.
- First Manhattan's portfolio value rose 4.7% quarter-over-quarter to $27.3B.
Based on First Manhattan's 13F filing for Q2 2023, filed 14 Aug 2023.